Latest Clinical Trial Updates for ATTR-CM and AL-CM

ATTR-CM poses a significant clinical challenge, affecting a growing number of individuals worldwide. In this broadcast entitled 'Latest Clinical Trial Updates for ATTR-CM and AL-CM', Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) with Dr Heather Landau (Memorial Sloan Kettering Cancer Center, US), Prof Dan Lenihan (Saint Francis Healthcare System, US) and Prof Joe Carver (University of Pennsylvania, US) will navigate through the intricacies of ATTR-CM, providing a comprehensive overview of ongoing clinical trials, emerging therapeutic modalities, and the evolving landscape of patient management. 

Join us as the faculty explore the latest findings, discuss potential implications for clinical practice, and address the challenges and opportunities within the ATTR-CM research. 

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.

This broadcast is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

Support Statement
This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BMS/Pfizer Alliance and Sumitomo Pharma through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.